Clinical Outcomes

Overview

Use of CareLink^® software led to significant A1C reductions for patients overall and proved especially beneficial for patients with limited access to clinics.

Overall A1C Reduction

On average, CareLink users improved their A1C levels, from 8.0 to 7.7, vs the no-access group* (8.0 to 8.1) and the non-user group† (8.9 to 9.0).¹

Improve Therapy for Patients With Limited Access

Amongst rural patients,‡ those who used CareLink were able to achieve reduced A1C levels, from 7.9 to 7.4, when compared to patients who did not use CareLink (9.2 to 9.2) or did not have access to CareLink (8.1 to 8.0).¹

Rural CareLink users were able to reduce their A1C despite having fewer office visits than urban patient groups§ (2.8 vs 3.5).¹

Establish a plan with your healthcare professional for rapidly identifying and treating both hypoglycemia and hyperglycemia, to prevent the onset of DKA and possible hospitalization. Act quickly to respond to out-of-target blood glucose. Notify your healthcare professional of low blood glucose requiring assistance or of high blood glucose, or of an increased frequency in low or high blood glucose.

For complete safety information, including contraindications, warnings/complications, and potential complications, see product label or visit the Indications, Safety, and Warnings page.

* CareLink no-access group did not have CareLink software.
^† CareLink non-users had CareLink Software access but did not use it.
^‡ Rural patients defined as living 1 hour or more away from the clinic.
^§ Urban patients lived less than an hour away from the clinic.